GBA Gene Mutation
8
3
3
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (8)
The GBA Multimodal Study in Parkinson's Disease
Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers
World Data on Ambroxol for Patients With GD and GBA Related PD
Ambroxol as a Disease-modifying Treatment in GBA-PD
LRRK2, GBA and Other Genetic Biomarkers in Eastern European (Ashkenazi) Jews With and Without Parkinson's Disease
Drug Discovery for Parkinson's With Mutations in the GBA Gene
High-Dose Ambroxol in GBA1-Related Parkinson
Evaluation of the Frequency and Severity of Sleep Abnormalities in Patients With Parkinson's Disease